2 weeks Ago By Defense World Staff
Natixis Advisors LLC acquired a new stake in Haemonetics Co. (NYSE:HAE – Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund acquired 15,294 shares of the medical instruments supplier’s stock, valued at approximately $1,194,000.
Several other institutional investors have also added to or reduced their stakes in the business. Arizona State Retirement System increased its stake in shares of Haemonetics by 1.2% in the fourth quarter.
Arizona State Retirement System now owns 14,853 shares of the medical instruments supplier’s stock worth $1,160,000 after purchasing an additional 181 shares in the last quarter. Parkside Financial Bank & Trust boosted its holdings in Haemonetics by 25.6% in the 4th quarter.
Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock worth $92,000 after buying an additional 240 shares during the period. HighTower Advisors LLC grew its stake in Haemonetics by 7.8% in the 4th quarter.
HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier’s stock valued at $262,000 after buying an additional 244 shares in the last quarter. Isthmus Partners LLC raised its holdings in Haemonetics by 1.1% during the 4th quarter.
Isthmus Partners LLC now owns 40,220 shares of the medical instruments supplier’s stock valued at $3,140,000 after acquiring an additional 450 shares during the period. Finally, KBC Group NV lifted its position in shares of Haemonetics by 54.6% during the fourth quarter.
KBC Group NV now owns 2,016 shares of the medical instruments supplier’s stock worth $157,000 after acquiring an additional 712 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.
Haemonetics Trading Down 1.6 %HAE opened at $63.39 on Wednesday.
The firm has a market capitalization of $3.18 billion, a price-to-earnings ratio of 24.96, a PEG ratio of 1.
11 and a beta of 0.43. Haemonetics Co.
has a one year low of $58.80 and a one year high of $97.97.
The business has a 50 day simple moving average of $66.66 and a two-hundred day simple moving average of $74.89.
The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.
55. Haemonetics (NYSE:HAE – Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.
19 EPS for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01).
Haemonetics had a return on equity of 23.66% and a net margin of 9.47%.
Analysts predict that Haemonetics Co. will post 4.55 EPS for the current year.
Analyst Upgrades and DowngradesSeveral equities analysts have recently weighed in on HAE shares. StockNews.com cut Haemonetics from a “buy” rating to a “hold” rating in a research report on Saturday, February 15th.
Raymond James reaffirmed a “strong-buy” rating and set a $115.00 target price (down previously from $120.00) on shares of Haemonetics in a report on Friday, February 7th.
Needham & Company LLC lowered their price target on shares of Haemonetics from $108.00 to $104.00 and set a “buy” rating on the stock in a report on Tuesday, March 18th.
JPMorgan Chase & Co. started coverage on shares of Haemonetics in a research note on Friday, December 6th. They set an “overweight” rating and a $116.
00 price objective for the company. Finally, Barrington Research decreased their target price on shares of Haemonetics from $108.00 to $95.
00 and set an “outperform” rating on the stock in a report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $101.
22.Get Our Latest Research Report on HaemoneticsHaemonetics Company Profile (Free Report)Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.
See AlsoFive stocks we like better than HaemoneticsRoth IRA Calculator: Calculate Your Potential ReturnsInnovation Incubators: Survey of Entrepreneurs Reveals The Cities Most Supportive of StartupsHow to Use Stock Screeners to Find StocksNVIDIA Insiders Sell: This Is What It Means for the Market Options Trading – Understanding Strike PriceSpace Stocks Bottoming: Which Are Positioned Best for a Bounce?.
